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Abstract: Parkinson’s disease is most commonly treated with a range of pharmacotherapeutics, 
with the more recent introduction of surgical techniques including deep-brain stimulation. 
These have limited capabilities to improve symptoms of the disease in more advanced stages, 
thus new therapeutic strategies including the use of viral vectors and stem cells are in devel-
opment. Providing a continuous supply of dopamine to the striatum in an attempt to improve 
the treatment of motor symptoms using enzymes in the dopamine synthesis and machinery is 
one approach. Alternatively, there are tools which may serve to both protect and encourage 
outgrowth of surviving neurons using growth factors or to directly replace lost innervation by 
transplantation of primary tissue or stem cell-derived dopaminergic neurons. We summarize 
some of the potential therapeutic approaches and also consider the recent EU directives on 
practical aspects of handling viral vectors, cells and tissues, and in the running of clinical trials 
in Europe which impact on their development.
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Parkinson’s disease (PD) is one of the most common neurodegenerative diseases 
affecting around 1%–2% of the population over 70 years of age (MacDonald et al 
2000). Motor symptoms are typically ﬁ  rst observed as tremor in one extremity; the 
disease then continues its relentless progression throughout the body. It causes not only 
the cardinal symptoms of resting tremor, postural instability, rigidity, bradykinesia, 
and akinesia but also many other symptoms including autonomic dysfunction, depres-
sion, and sleep disturbances which can present prior to the motor disorder (Chaudhuri 
et al 2006). Many of the motor symptoms are ascribed to the speciﬁ  c deterioration of 
dopaminergic neurons of the nigrostriatal pathway that typiﬁ  es the disease. Pigmented 
cell bodies residing in the A9 substantia nigra region of the hindbrain with heavily 
branched projections targeted mainly at the putamen degenerate retrogradely, striatal 
innervation being lost ﬁ  rst, followed by cell body deterioration. Additional pathology in 
speciﬁ  c neurochemical systems is observed in the loss of serotonergic, noradrenergic, 
and cholinergic cells. The pathological criteria for diagnosis are cellular protein inclu-
sions termed Lewy bodies (Jellinger 1991). The extent of these varies enormously 
from patient to patient and may include areas outside of the nigrostriatal system, for 
example, the cortex.
The primary therapeutic antiparkinsonian approach in the clinic at present is 
pharmaceutics-based. Symptomatic treatments are highly effective at managing the 
motor consequences of nigrostriatal loss, especially in the early stages. However, there is 
currently no conclusive evidence that any drug licensed for PD has the ability to prevent 
the relentless wave of degeneration the disease typiﬁ  es. Ergot and non-ergot derived 
dopamine D2 receptor agonists and L-dopa, the metabolic precursor to dopamineNeuropsychiatric Disease and Treatment 2008:4(5) 836
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(with a peripheral decarboxylase inhibitor), constitute the 
mainstay therapies, although there are also a number of 
adjunctive therapies in use. Over recent years, there has 
been increasing interest in surgical approaches, which are 
now in routine use for speciﬁ  c symptoms in many countries. 
Previously ablative surgeries such as pallidotomy or sub-
thalamotomy have been successfully performed and found 
to improve certain aspects of motor function. However, this 
has generally now been replaced by the more easily reﬁ  ned 
approach of deep-brain stimulation (DBS), involving high 
frequency stimulation of speciﬁ  c nuclei, most commonly 
the subthalamic nucleus. While generally effective, these 
current treatments also have signiﬁ  cant inadequacies. The 
long term use of drug treatments produces multiple side-
effects, not least the ‘wearing off’ phenomena in which the 
efﬁ  cacy of the drug wanes, giving way to the development 
of motor ﬂ  uctuation and the onset of abnormal involuntary 
movements known collectively as ‘dyskinesia’. As the disease 
progresses, ever-increasing doses of L-dopa are required to 
control the primary symptoms, which exacerbates the side 
effects, eventually limiting treatment options. There are also 
symptoms that are non-responsive to drug treatment, such as 
postural instability and dementia. When applied appropriately 
DBS can be highly effective at relieving some motor symp-
toms and reducing the need for L-dopa, but it is costly and 
generally only considered for patients with late stage disease 
and without signs of dementia. Furthermore, there is concern 
about signiﬁ  cant side effects such as cognitive decline, which 
may be permanent.
As a result of these inadequacies, alternative and supple-
mentary symptomatic therapies are still being sought and 
a number of different pharmacotherapeutic avenues are 
being explored. These are reviewed in more detail else-
where (see Schapira et al 2006) but brieﬂ  y include other 
potential drugs targeting the dopaminergic system such as 
dopamine-modulating agents (Ekesbo et al 2000; Pirker 
et al 2001) and monoamine uptake inhibitors (Frackiewicz 
et al 2002; Bara-Jimenez et al 2004). Furthermore, drugs 
affecting the serotonin system, such as the 5-HT1A agonist 
sarotizan (Bara-Jimenez et al 2005; Goetz et al 2007); 
adenosine A2A antagonists; opioids; and glutamatergic and 
GABAergic drugs are at different stages of development. 
These compounds can act at several levels: either acting to 
directly replace the lost dopaminergic transmission at the 
level of the striatum; acting through alternate mechanisms 
in the striatum to effect striatal output; or targeting down-
stream nuclei in the basal ganglia to redress the imbalance 
in motor output signals.
Some of the aforementioned symptomatic therapies 
are purported to have neuroprotective potential on the 
remaining dopaminergic neurones. The rate of progression 
of the disease on patients taking the selective irreversible 
monoamine oxidase inhibitors selegiline is slower than 
those on L-dopa alone suggesting that there is a supplemen-
tary action in slowing the degenerative process (Shoulson 
1998). However, the data are ambiguous and the design of 
the clinical trials cannot rule out an entirely symptomatic 
effect. Multiple mechanisms have been proposed to be 
involved in the degenerative process, many overlapping with 
other neurodegenerative diseases. Thus, anti-oxidants, like 
coenzyme Q10 and vitamins C and E, are being evaluated 
in different disease conditions for their ability to slow down 
the disease process.
With the exception of targeted surgical intervention all 
of the above are systemic therapies, however a generation 
of potential therapies are under development, which involve 
more directed cellular approaches to the treatment of PD. 
In this review, we examine the different methodological 
approaches to deliver symptomatic, neuroprotective and 
neurorestorative agents directly to the affected areas of 
the brain.
The focus of degeneration in PD is the nigrostriatal 
dopaminergic loss, with the greatest impact being in the 
loss of input to the striatum. Rebuilding the nigrostriatal 
tract in an adult in the absence of developmental signals and 
speciﬁ  c growth signals, has proved highly complex and thus 
restorative approaches are predominantly focused on placing 
dopamine cells into the nigrostriatal dopamine neuron target 
site. Methodological approaches include the use of viral 
vectors, either directly administered or used to alter cell 
function prior to transplantation. Furthermore, donor cells 
can either be transplanted and allowed to integrate with the 
host environment or encapsulated to facilitate removal. Their 
development has not only entered novel scientiﬁ  c arenas but 
has raised practical and ethical concerns which have been 
addressed at international level with the introduction of new 
EU legislation to govern these processes. We focus on the 
areas of this legislation that has greatest practical impact 
on researchers throughout Europe in the context of these 
developing therapies.
Symptomatic strategies
The degeneration of dopaminergic neurons in PD causes the 
striatum to be depleted of not only dopamine, but also the 
dopamine synthesizing machinery that is present in terminal 
axonal regions. There is great interest therefore, in enhancing Neuropsychiatric Disease and Treatment 2008:4(5) 837
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either L-dopa or dopamine production by equipping other 
cells in the striatum with the necessary ‘tools’ through the use 
of viral vectors (Carlsson et al 2007). L-dopa is converted to 
dopamine either by the remaining dopaminergic terminals or 
by serotonergic terminals or glia in the striatum (Tanaka et al 
1999; Maeda et al 2005). The production of dopamine from 
L-tyrosine is a multistage process, the rate-limiting enzyme 
being tyrosine hydroxylase, which converts L-tyrosine to 
the dopamine precursor L-dopa. However, supplementation 
with additional tyrosine hydroxylase alone is not a viable 
approach as its enzymatic functioning requires the pres-
ence of a co-factor tetrahydrobiopterin (BH4) (Fukushima 
et al 1977). Hence, in order to produce functional beneﬁ  t, 
a combination of viral vectors expressing both GTP cyclo-
hydrolase 1 (GCH1; a key enzyme in BH4 synthesis) and 
tyrosine hydroxylase is required. The advantage of the use 
of viral vectors in this context is the continuous delivery of 
dopamine. Continuous enteral infusion of L-dopa or subcuta-
neous apomorphine signiﬁ  cantly reduces motor ﬂ  uctuations 
and dyskinesia demonstrating that the pulsatile changes in 
dopamine levels after oral L-dopa administration may be 
responsible for their generation (Sage and Mark 1992; Syed 
et al 1998; Poewe and Wenning 2000; Nyholm et al 2003). 
Viral vector enhanced production of L-dopa should produce 
a constant level of dopamine to provide good therapeutic 
beneﬁ  t but without the development of dyskinesia. Results 
in the 6-OHDA lesioned rat demonstrate robust behavioral 
recovery as assessed by amphetamine-induced rotation and 
the cylinder test of forelimb asymmetry concurrent with 
a reduction in L-dopa induced dyskinesia (Carlsson et al 
2005). L-dopa delivered to the periphery is subjected to 
premature conversion to dopamine that necessitates the 
co-administration of a peripheral amino acid decarboxylase 
inhibitor (AADC) to increase central uptake of L-dopa. 
Viral vector mediated enhancement of dopamine synthesis 
in the striatum would make the use of such supplementary 
oral drugs redundant. Conversely, it has inspired the use 
of a triple viral approach delivering AADC intrastriatally 
in addition to TH and GCH1 to facilitate the conversion of 
L-dopa to dopamine (Sun et al 2004). This approach, using 
both AAV and lentiviral vectors, improves motor function 
in rats and primates and increases dopamine levels in the 
affected striatum (Muramatsu et al 2002).
A potentially simpler approach is to transduce with a viral 
vector delivering AADC alone (Leff et al 1999). As AADC 
is lost concomitantly with the degenerating dopaminergic 
neurons, increasing conversion of  L-dopa to dopamine will 
maximize the efﬁ  cacy of the absorbed L-dopa. However, 
this apparently more simple approach could be more risky 
as there is no inherent feedback mechanism in the control of 
AADC activity and increased concentrations of AADC could 
lead to dopamine over production. While TH is inhibited by 
dopamine, self-limiting dopamine production, AADC has 
no such innate control mechanism (Carlsson et al 2007). 
This could lead to even greater degrees of ﬂ  uctuating striatal 
dopamine and exacerbate motor disturbances.
One consequence of dopaminergic input in the striatum 
is disinhibition of the subthalamic nucleus. This is the most 
common target of DBS, in which high frequency stimula-
tion acts to reduce the activity of this nucleus. Similarly, 
transfection with an AAV encoding the gene for glutamic 
acid decarboxylase, synthesizing the inhibitory transmitter 
GABA has been shown to reduce the excitatory output from 
the subthalamic nucleus, improving motor cortex activity 
and consequently in both rodent and macaques models of 
PD restoring motor function (Luo et al 2002; Lee et al 2005; 
Emborg et al 2007).
Neurotrophic factors
In the region of 70%–80% of striatal dopamine is depleted 
before signiﬁ  cant motor symptoms are detected in patients 
(Bernheimer et al 1973). This suggests that there is a signiﬁ  -
cant pre-symptomatic interval during which some degree of 
cellular plasticity allows the brain to compensate for the lost 
innervation. Sprouting of remaining dopaminergic ﬁ  bres after 
neurotoxic challenge has been reported in 6-OHDA lesion 
models of  PD, and changes in presynaptic terminals, upregu-
lation of AADC levels to increase dopamine conversions and 
reduced dopamine transporter have been demonstrated both 
in MPTP primate models and PD patients. These compensa-
tory mechanisms have the potential to be harnessed to further 
delay the onset of symptoms or prevent deterioration.
Neurotrophic factors are a family of protein growth 
factors that regulate components of neuronal growth. Neuron 
number, branching, axon and dendrite length, neuronal phe-
notype and synaptic plasticity can all be regulated through 
their action at speciﬁ  c receptors. Due to the differential 
expression of these growth factors and their receptors, differ-
ent neuronal populations are inﬂ  uenced to a greater or lesser 
extent by each factor. GDNF, neurturin, CNFT and BDNF, 
to name but a few, have all been evaluated in animal models 
of PD to determine their effects on dopaminergic neurons. 
Many molecules have been shown to be neuroprotective, 
reducing dopaminergic cell death following toxic challenges. 
GDNF has been the most potent trophic molecule used so 
far and in animal models of PD has clearly demonstrated a Neuropsychiatric Disease and Treatment 2008:4(5) 838
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capacity to protect neurons against a toxic challenge (Zurn 
et al 2001; Sherer et al 2006; Patel and Gill 2007). However, 
these factors require application directly into the relevant 
area as they do not cross the blood-brain barrier and even 
when delivered directly into the brain, the precise location 
of the cannula seems critical. The ﬁ  rst studies used intra-
cerebroventricular pumps containing GDNF, which failed 
to improve symptoms and were associated with serious side 
effects likely to be as a result of the extrastriatal delivery 
(Kordower et al 1999; Nutt et al 2003).
The ﬁ  rst successful application of GDNF was in the form 
of a pump installed in the abdomen that released GDNF 
into the putamen via a thin cannula. The ﬁ  rst intraputam-
inal phase I open label safety trial on 5 patients produced 
dramatic improvements in motor function in all of the patients 
(Gill et al 2003). However, a double-blind placebo-controlled 
trial sponsored by Amgen designed to further examine 
the beneﬁ  ts of this approach was prematurely terminated 
(Lang et al 2006). The primary outcome measures had not 
been achieved and anti-GDNF antibodies had been found in 
some patients indicating a possible autoimmune response. 
Furthermore, very high doses of GDNF administered to 
primates had produced cerebellar lesions. Various technicali-
ties have been given for the failure of this trial including the 
efﬁ  ciency of delivery due to use of different cannulae from 
the initial trial (Lang et al 2006).
Since the potential of GDNF has been determined, there 
have been alternative approaches to the delivery of the 
growth factor. The use of viral vectors to engineer cells to 
produce GDNF within the striatum is being considered to 
produce a continuous supply, rather than the re-ﬁ  lls required 
by a pump. The viral vector could be injected directly in 
vivo transfecting the host striatal cells and enabling them 
to express GDNF. In 6-OHDA lesioned rats, transfection 
of adeno-associated viral vectors expressing the GDNF 
protein have signiﬁ  cantly protected dopaminergic termi-
nals in the striatum from insult by 6-OHDA in both rodents 
and non-human primates (Choi-Lundberg et al 1998; Kirik 
et al 2000; Wang et al 2002; Eslamboli et al 2003). Prob-
lems with this approach include control of the expression 
of the vector should there be side effects. It has already 
been demonstrated that aberrant sprouting of ﬁ  bres and 
downregulation of tyrosine hydroxylase expression occurs 
(Georgievska et al 2002; Rosenblad et al 2003) which 
could potentially limit functional recovery in the long term. 
Other possible approaches are to transfect cells in vitro and 
either transplant these GDNF producing cells directly or, 
more safely, deliver encapsulated cells in a semi-permeable 
membrane. Such encapulsated GDNF-producing cells have 
protected nigrostriatal dopaminergic neurons from 6-OHDA 
toxicity (Shingo et al 2002; Yasuhara et al 2005) and also 
shown a neurorestorative action by increasing dopamine 
ﬁ  bre density, an effect that was sustained following capsule 
removal (Sajadi et al 2006). The advantages to this approach 
are that multiple devices could be used to provide GDNF 
throughout the putamenal area, the lower levels delivered in 
this approach should minimize side effects and the risks of 
cerebellar toxicity and antibody generation highlighted by 
the Amgen trial. As with direct viral vector administration, 
long-term safety trials ﬁ  rstly in non-human primates need to 
be carried out to assess the ease of implantation and retrieval, 
efﬁ  cacy and also toxicity and immunogenicity (Lindvall and 
Wahlberg  2008). One disadvantage of this approach concerns 
the fact that capsules have a limited lifespan and therefore 
surgery would need to be repeated.
Other growth factors of the same family, neurturin and 
CDNF, have also been proposed as potential therapeutics. 
Both growth factors protect dopaminergic neurons from toxic 
insult in vivo (Rosenblad et al 1999; Li et al 2003; Lindholm 
et al 2007) but while CDNF is still in the early stages of 
preclinical studies, neurturin has progressed to clinical tri-
als using intrastriatal delivery through an adeno-associated 
virus type II (AAV2). Preliminary safety and efﬁ  cacy data 
from the phase I clinical trial of 12 patients are encouraging 
with no signiﬁ  cant side effects and an improvement of up 
to 36% in the UPDRS score in 9 of the 12 patients (Marks 
2006) and phase II trials are underway.
Cell transplantation
Transplantation of primary ventral mesencephalic tissue 
into the striatum aims to restore brain circuitry and function 
lost as a result of PD. The main objective of primary tissue 
transplantation has been to provide proof-of-principle that 
grafted dopaminergic neurons can i) survive and restore 
regulated dopamine release, ii) integrate with the host brain 
to reinstate frontal cortical connections and activation, 
and iii) lead to measurable clinical beneﬁ  ts together with 
improved quality of life.
Preclinical work in animal models of  PD has shown that 
grafted dopaminergic neurons, extracted from the developing 
ventral mesencephalon (VM) can survive, reinnervate the 
lesioned striatum, and improve motor function (Bjorklund 
1992; Herman and Abrous 1994; Winkler et al 2000). Over 
the past two decades, a series of open-label clinical trials have 
provided convincing evidence to show that human embryonic 
nigral neurons taken at a stage of development when they Neuropsychiatric Disease and Treatment 2008:4(5) 839
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are committed to a dopaminergic phenotype can survive, 
integrate and function over a long time in the human brain. To 
date, approximately 350 patients with PD world-wide have 
received primary tissue transplantation. Based on a small 
number of carefully controlled clinical trials, there is good 
evidence of graft survival, with grafted neurons developing 
afferent and efferent projections with the host neurons. Long-
term survival of dopaminergic grafts is possible up to 10 years 
after transplantation (Piccini et al 1999), and there have been 
no reported cases of overt immunorejection even after several 
years of withdrawal from immunosuppression (Olanow et al 
2003). Evidence from PET scanning has revealed signiﬁ  cant 
increases in activation in the areas reinnervated by the grafted 
cells, and longitudinal clinical assessments indicate signiﬁ  -
cant functional recovery for motor control, in some cases for 
more than 10 years (Dunnett et al 2001; Lindvall and Hagell 
2002; Bjorklund et al 2003). In the most successful cases, 
patients have either reduced dependency for or completely 
withdrawn from L-dopa treatment. Post-mortem studies 
similarly show good survival of transplanted neurons and 
well integrated grafts (Kordower et al 1995).
Two NIH sponsored double-blind placebo-controlled 
clinical trials have been unable to replicate the scale of 
these clinical beneﬁ  ts and reported severe graft-induced 
dyskinesias during “off” phases (Freed et al 2001; Olanow 
et al 2003). The precise mechanism responsible for these 
dyskinesias remains unknown but it does not appear to be 
related to graft overgrowth resulting in excessive dopamine 
release (Hagell et al 2002; Lane et al 2006). One possibility 
surrounds the quality of dissected tissue. Successful trials 
have used either freshly dissected tissue or tissue that has 
been stored in culture for only a few days. One of the trials 
reporting cases of severe dyskinesias used tissue stored in 
culture for up to four weeks (Freed et al 2001) and it may 
be that holding tissue in this way reduces its dopaminergic 
composition (Hagell et al 2002). A further issue concerns 
the identiﬁ  cation of dense hyperdopaminergic areas within 
the graft of some patients with graft-induced dyskinesias 
(Ma et al 2002). This may have caused uneven striatal inner-
vation and excessive dopamine release into non-reinnervated 
areas (Winkler et al 2005). Finally, it should be noted that 
these studies were severely under-powered, and moreover, 
subsequent follow-up data have suggested some evidence 
of efﬁ  cacy.
It is also possible that variable side effects of graft-
induced dyskinesias are related to patient selection. Greater 
functional improvement is associated with younger patients, 
and in patients with less advanced disease. This is most 
likely because the neuropathology is relatively conﬁ  ned 
to the nigro-striatal pathway and may have better trophic 
support compared to patients with more advanced disease. 
Furthermore, patients with more advanced disease and who 
have become dyskinetic from long-term use of L-dopa may 
have increased susceptibility to developing graft-induced 
dyskinesias (Piccini et al 2005; Lane et al 2006).
VM grafts have thus far been placed in the putamen, and 
patients who received most beneﬁ  t from these transplants 
have had pathology restricted to this area both prior to and 
after transplantation (Piccini et al 2005). Given the range 
of symptoms and pathology with different levels of sever-
ity seen in PD patients it has been proposed that placement 
of VM grafts should be based on patient-speciﬁ  c proﬁ  les 
determined by FD-PET imaging (Winker et al 2005). The 
ﬁ  ndings observed in the NIH sponsored trials have led to 
stimulating and extensive review of the different method-
ological approaches used by different centers to procure, 
handle and store fetal tissue. It is possible that differences 
between these approaches may account for the variability 
in graft-induced functional recovery. A recent review by 
Winkler et al (2005) identiﬁ  es the following aspects requir-
ing harmonisation ahead of further clinical trials: dissection 
of the tissue, the age of donor foetus, the length and type 
of storage after dissection, the method of dissociation prior 
to grafting (pieces vs suspension), and the composition of 
medium used for storage and/or implantation. The limited 
availability of tissue and the need for multiple donors for 
single patients leads to problems of co-ordinating and stor-
ing tissue prior to transplantation. The quality of the tissue 
is intrinsically variable and reaching consistent standards of 
reproducible preparation, quality control and safety assess-
ment to compare accurately the safety and efﬁ  cacy of this 
therapy across different trials are very difﬁ  cult to achieve 
through this source of tissue. Therefore, while the use of 
primary tissue has allowed the proof-of-principal studies to 
be completed, permitting the accumulation of a substantial 
body of experience, they have also reinforced the fact that 
alternate source of cells are necessary for transplantation to 
become a viable therapeutic option.
Stem cells
Stem cells could provide one such source and would over-
come the issue of limited availability of fresh primary fetal 
cells. A wide range of stem cells are being investigated as 
potential sources of dopaminergic neurons for transplantation 
and while it is beyond the scope of this review to go through 
each of these in detail we will give a short update as to the Neuropsychiatric Disease and Treatment 2008:4(5) 840
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progress being made (for more detailed review see Dass et al 
2006; Morizane et al 2008; Zietlow et al 2008). Stem cells 
can be obtained from various sources including those derived 
from the early developing embryo (embryonic stem cells), 
or later in development from gonadal regions (embryonic 
germ cells), from the developing or adult brain (neural stem 
cells) and other tissues such as bone marrow, umbilical 
cord and amniotic ﬂ  uid and very recently, the carotid body 
(mesenchymal stem cells). The majority of research thus far 
with respect to the formation of dopaminergic neurons for 
the treatment of PD is in embryonic stem cells and neural 
stem cells. Dopaminergic neurons are more easily obtained 
from neural stem cells in the developing VM than other parts 
of the developing central nervous system but the number 
of dopaminergic cells produced is still very low. Despite 
genetic manipulation and the addition of various growth 
and differentiation factors, generating large numbers of 
dopaminergic cells from this cell type has had mixed results 
(Wang et al 2004; Yang et al 2004). However, greater success 
has been achieved with the more complex embryonic stem 
cells. Derived from blastocysts donated following in vitro 
fertilization these cells are truly pluripotent. Promising data 
have been obtained with dopaminergic neurons derived from 
mouse ES cells, signiﬁ  cantly improving motor function in 
a rat model of PD (Kim et al 2002). However, directing the 
differentiation of human ES cells has proved complex and 
while 50% of cells spontaneously differentiate into neurons 
upon LIF withdrawal, few are dopaminergic. Thus, there is 
the need to develop protocols to ‘direct’ differentiation. The 
most successful published protocols describe multiple culture 
stages in which different transcription and growth factors are 
added at controlled time points (Perrier et al 2004; Roy et al 
2006). However, despite good yield of dopaminergic neurons 
in vitro, clinically relevant long-term survival and behavioral 
recovery in animal models rivalling that of primary tissue has 
yet to be convincingly demonstrated (Ben-Hur et al 2004; 
Park et al 2005; Brederlau et al 2006; Roy et al 2006). The 
use of embryonic stem cells is still ethically controversial 
and there is a risk of unregulated growth into undesirable cell 
types or tumor formation. Neuronal stem cells carry less risk 
in this respect but furthermore, unlike embryonic stem cells, 
which are only derived from the embryonic blastocyst, neural 
stem cells can be found both in embryonic neural tissue and 
also in speciﬁ  c neurogenic regions of the adult brain. If the in 
vivo survival of neural stem cells can be improved they hold 
the potential to provide autologous transplantation as patients 
provide the cells for their own recovery. Cell lines that also 
hold that potential and that could be obtained through less 
invasive means are carotid body and bone marrow derived 
mesenchymal stem cells.
Interestingly, stem cells may not just be useful as 
dopamine factories in the striatum. Recent studies in both 
rodent and primate models have shown signiﬁ  cant behav-
ioral recovery following transplantation with neural stem 
cells. In addition to the generation of a small population 
of dopaminergic neurons other cells within the graft were 
found to be releasing growth factors which are purported 
to exert neuroprotective or neuroregenerative inﬂ  uences 
(Redmond et al 2007; Yasuhara et al 2007). While more 
evidence needs to be accumulated on the longevity of this 
effect, it broadens the potential of neural stem cells from 
simple dopamine replacement to preserving and enhancing 
remaining dopaminergic neurons.
Neurogenesis
As mentioned above endogenous stem cells are present 
in speciﬁ  c regions of the brain. While the occurrence of 
neurogenesis in the striatum and substantia nigra is debated 
(Zhao et al 2003; Frielingsdorf et al 2004), one indisputable 
neurogenic region is the subventricular zone (SVZ) lying 
adjacent to the striatum. The cells in the region are an assort-
ment of stem and progenitor cells that have the potential to 
be mobilized and induced to differentiate by the presence 
of growth factors or other small molecules. In the normal 
condition 75%–99% or the cells differentiate into granular 
GABAergic neurons, with the rest forming periglomular 
neurons expressing either tyrosine hydroxylase or GABA. 
The control of proliferation and mobilisation of these cells 
may be dopaminergic as both MPTP and 6-OHDA mediated 
dopamine depletion reportedly decrease proliferation in this 
zone (Baker et al 2004; Hoglinger et al 2004). An additional 
source of endogenous source of new dopaminergic neurons 
may be in the recently described presence of tyrosine hydrox-
ylase positive cell bodies in the striatum, which increase in 
quantity with dopaminergic denervation (Dubach et al 1987; 
Betarbet et al 1997; Porritt et al 2000). This is believed to 
be a phenotypic switch in striatal neurons in response to 
low dopamine levels (Tande et al 2006). As yet there are no 
imminent therapeutic strategies heading towards the clinic 
that manipulate these endogenous systems but their potential 
is waiting to be harnessed. Therapeutic strategies to increase 
striatal dopamine could involve recruiting newly produced 
neurons in the SVZ and encouraging them to migrate into 
the striatum and differentiate into dopaminergic neurones or 
to stimulate cells resident in the striatum. In order for this to 
be achieved understanding more about these two processes Neuropsychiatric Disease and Treatment 2008:4(5) 841
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of neurogenesis and phenotypic switching in the striatum 
is necessary, determining the intrinsic or extrinsic factors 
responsible may provide an alternative set of mechanisms 
that could be utilized to treat PD.
Clinical trials of new therapies
Clinical trials of restorative therapy in PD must follow 
clinical and research governance frameworks to protect 
and promote the health and well-being of the patient at all 
times. Successful frameworks are structured around three 
main aims: establishing clear lines of responsibility and 
accountability, implementing the highest possible stan-
dards of clinical care, and promoting a constant dynamic of 
improvement. Within the European Union (EU), legislative 
acts known as EU directives, require EU member states to 
achieve a particular result without laying down the means of 
accomplishing that result, leaving the individual members 
to devise their own advisory and enforcement bodies. Here 
we describe two EU directives that need to be considered in 
clinical trials of restorative therapies for PD, whether of cell 
transplantation or gene therapy.
EU directive 2001/20/EC relating 
to the implementation of good 
clinical practice in the conduct 
of clinical trials on medicinal 
products for human use
The purpose and scope of this directive is to enhance the 
protection of human subjects enrolled in clinical trials of 
medicinal products, to ensure quality of conduct, and to 
standardize regulation and conduct of clinical trials across 
Europe. Clinical trials of medicinal products should adhere 
to current legislation, regulation and guidance including the 
principles of Good Clinical Practice (GCP); a set of inter-
nationally harmonized guidelines to serve the protection of 
human rights, safety and dignity whilst also assuring ethical 
and scientiﬁ  c integrity. The Directive details both ethical 
and scientiﬁ  c quality requirements for all levels of develop-
ing a clinical trial for a medicinal product from designing, 
conducting, recording and reporting in phase I–IV trials. The 
Directive emphasizes that the objective of a clinical trial is 
to establish safety and efﬁ  cacy a therapeutic intervention 
using one or more medicinal products. A clinical trial must 
obtain favorable opinion from a legally constituted Ethical 
Review Board. The conduct of a clinical trial should include 
statutory inspections by authorities able to verify levels 
of efﬁ  cacy and safety that are acceptable and compliant 
with GCP. Within Europe, the pharmacovigilance system 
Eudravigilance activates the immediate cessation of a trial 
with an unacceptable level of risk, exchanging information 
between Member States using shared databases. The pos-
sibility of adverse reactions means that sponsors of clinical 
trials must be able to provide insurance or indemnity to cover 
liability costs. Manufacturing and document archiving are 
further legislated in EU DIRECTIVE 2005/28/EC.
EU DIRECTIVE 2004/23/EC on setting 
standards of quality and safety 
for the donation, procurement, 
testing, processing, preservation, 
storage, and distribution of human 
tissues and cells
The use of human tissues and cells for transplantation has 
become a strong focus for therapeutic intervention in PD. 
The Directive only applies to the use of human tissue and 
cells used for clinical trials to the human body; it does not 
apply to in vitro research experiments or use in animal mod-
els of disease. The quality and safety of these substances 
must be maintained, in particular to prevent transmission of 
disease. Donated tissues and cells must be procured, tested, 
processed, preserved, and stored in accordance with vali-
dated and approved safety measures. In order to regulate the 
highest possible quality control and assurance surrounding 
the handling, preparation and storage of these substances 
for use in clinical trials, laboratory conditions must achieve 
Good Manufacturing Practice (GMP) standards. GMP sets 
out highly speciﬁ  ed conditions of laboratory practice and 
regulation put in place to ensure successful production and 
quality control of the therapeutic product. In light of the 
EU directive, the UK Human Tissue Act (2004) sets out a 
new legal framework for the storage and use of tissue from 
the living, and the removal, storage and use of tissues and 
organs from the dead. The Human Tissue Authority (HTA; 
www.hta.gov.uk) is the regulatory body for all matters 
concerning the removal, storage, use and disposal of human 
tissue for scheduled purposes. The HTA provides advice 
and guidance, issues codes of practice and is responsible 
for licensing establishments. The fundamental principle 
of the HTA is that of consent in relation to the retention 
and use of living patients’ organs and tissue for particular 
purposes beyond their diagnosis and treatment, and consent 
surrounding the removal, retention and use of tissue from 
those who have died (where consent is obtained either by 
those individuals in life, or after death by someone nominated Neuropsychiatric Disease and Treatment 2008:4(5) 842
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by or close to them). The practicalities of this legislation are 
that GMP standards have to be adhered to in the handling 
and processing of human tissue for transplantation. As such, 
European groups intending to perform transplantations have 
had to install (at their own cost) facilities and equipment and 
provide training to gain GMP approval. There is a vastly 
more detailed paper trail that will ensure the tracking of 
individual samples from derivation at elective termination to 
eventual transplantation, and processes previously validated 
have to be amended to ensure that all products involved in 
the processing of the tissue are of GMP status.
Considerations in the development 
of treatments for PD
Beyond the legislative constraints that arise for all disease 
treatment strategies using at viral vector or human tissue 
methodologies, there are practical and ethical issues pertain-
ing to the treatment of PD that require consideration.
Conclusive diagnosis
A major concern with the treatment of motor disorders and 
the successful evaluation of future therapies in small scale 
clinical trials is that there is no conclusive pre-mortem diag-
nosis of PD. Lewy bodies remain the deﬁ  ning pathological 
hallmark in addition to the presence of nigrostriatal degen-
eration, the presence of which cannot be conﬁ  rmed until 
post-mortem. Unfortunately the motor symptoms alone are 
unable to provide a conclusive diagnosis of PD as there is 
a broad spectrum of phenotypes and a distinct overlap with 
Parkinson’s plus syndromes, even responsiveness to L-dopa, 
typical of PD, can be confounding in the case of multiple 
systems atrophy, as early stage patients can present both with 
symptoms indistinguishable from PD and a responsiveness 
to L-dopa. Furthermore, even with a conﬁ  dent diagnosis of 
PD this in itself incorporates a range of disease phenotypes 
which may correspond to subgroups of patients for whom 
different treatment approaches may be more appropriate or 
more effective (Foltynie et al 2002).
When to intervene?
The stage of the disease at which the trials should be car-
ried out is an ongoing debate. Where existing therapies 
are capable of alleviating symptoms it is more complex 
to involve these patients in clinical trials of highly novel 
therapeutic approaches. However, patients in a more 
advanced state may not be the optimum patient group to 
beneﬁ  t from the treatment strategy. Inclusion criteria for 
trials of transplantation of embryonic cells have included 
a minimum of 7 years of treatment and the presence of 
intractable problems which indicates patients in the more 
advanced stages of disease. All these patients had been 
taking L-dopa for several years and therefore had estab-
lished L-dopa induced dyskinesia. Rodent experiments 
have demonstrated an association between the severity of 
these behaviors or exposure to L-dopa prior to transplanta-
tion with the extent of graft-induced dyskinesia (Lane et al 
2006). Earlier stage patients are less likely to have devel-
oped intractable L-dopa induced dyskinesia and therefore 
this may be a more suitable target group of patients.
Risks and predicted side effects
The risks to patients undergoing primary or stem cell therapy 
must all be considered and eliminated or minimized in pre-
clinical experimentation prior to initiation of a clinical trial, 
however this is not possible. Some patients that received 
dopaminergic fetal tissue transplants into the striatum 
developed the unpredicted side effect of ‘off  ’ medication 
dyskinesia. While the reasons for this side effect are becom-
ing clearer it heightens the need for careful observation to 
identify unexpected side effects both on and off medication. 
This development has hindered the progress of primary and 
stem cell transplantations and will also impact upon viral 
vector clinical trials. Other risks to patients undergoing cell 
transplantation include the risk of tumor formation, the migra-
tion of cells to inappropriate brain regions, immune rejection 
of the cells in addition to the inherent risks of neurosurgery 
such as hemorrhage and post-operative infection.
Gene therapy carries its own associated risks, and 
although huge progress has been made in recent years, 
improvements in the safety of viral vectors have to be 
demonstrated. The risks include insertional mutagenesis 
associated with retroviral vectors (implicated in the devel-
opment of leukemia in X-SCID sufferers in France). This 
is avoided with the use of adeno-associated viruses but the 
potentially high immunogenicity has also led to recommen-
dations from the UK Gene Therapy Advisory Committee 
(GTAC) that more detailed immune status and cytokine 
proﬁ  ling of the patients is carried out throughout the trial 
(Relph et al 2004). The ﬁ  rst trials carried out with the AAV2 
containing neurturin have not demonstrated any adverse 
side effects, however this only encompasses a small group 
of patients followed over a short period of time. Unlike 
cell transplantation, there have been no proof-of-principle 
experiments helping guide new clinical trials and long-term 
safety and efﬁ  cacy trials still need to be carried out. The 
recent EU directives on good practice in clinical trials and Neuropsychiatric Disease and Treatment 2008:4(5) 843
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the manufacture of products for clinical use detailed above 
have inﬂ  uenced these processes.
Placebo effects and sham surgery
As with other diseases, there is evidence that this patient 
group is subject to placebo effects (de la Fuente-Fernandez 
and Stoessl 2002). This is commonly seen with non-invasive 
drug treatments but has also been demonstrated with DBS 
(de la Fuente-Fernandez 2004). The ethics of blinded sham 
surgery to demonstrate clinical efﬁ  cacy is also a contentious 
area with differing opinions from scientists, patients and 
public health departments (Boer and Widner 2002; Kim et al 
2005; Polgar and Ng 2007; Frank et al 2008). Arguments 
include the level of risk and associated costs of ‘unnecessary’ 
surgical procedures against the validity of non-blinded trials 
which could lead to false positive results, although the accept-
ability of this approach to members of the public appears to 
depend on their disease status, those without PD tending to 
be more willing to risk sham surgery (Frank et al 2008).
Outcome measures
Restorative therapy in PD aims to reinstate brain circuitry 
and function lost as a consequence of progressive neuro-
degenerative disease. The clinically beneﬁ  cial effect of a 
therapy is dependent on two main issues: ﬁ  rstly, whether 
the therapy will survive and replace lost neurons in the 
place(s) where required, and secondly, whether the therapy 
can restore normal function effectively. Assessing efﬁ  cacy 
depends on sensitive and reliable outcome measures, ide-
ally well-validated clinical and biological markers collected 
systematically over a longitudinal period. To date, previous 
and on-going clinical trials of restorative therapy in PD have 
relied on extensive assessment protocols, eg, cell therapies 
follow CAPIT: Core Assessment Protocol for Intracerebral 
Transplantation, capturing longitudinal data on clinical and 
imaging markers. In spite of such existing protocols, there 
is a continued demand for the development of more accurate 
and reliable outcome measures to assess the scientiﬁ  c and 
economic feasibility of future restorative therapy.
There are many new avenues of therapy on the horizon 
for the treatment of PD. However, in order for them to suc-
cessfully reach the clinic as a mainline treatment clinical 
trials will have to demonstrate proof of principle, safety and 
efﬁ  cacy, as the primary fetal tissue studies have done. There 
is increasing amounts of legislation surrounding the ethical 
and practical issues which must be considered in the planning 
of new clinical trials as well as adequate designs to ensure 
conclusive data are obtained and the true potential of these 
novel therapies is realized.
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